1:39 AM
 | 
Apr 03, 2019
 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration.

AgomAb Therapeutics N.V. (Ghent, Belgium) also announced the hiring of Tim Knotnerus as CEO and Torsten Dreier as chief development officer....

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >